AstraZeneca’s (AZN) Imfinzi in combination with standard-of-care FLOT chemotherapy has been recommended for approval in the European Union for the treatment of adult patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers. The regimen includes neoadjuvant Imfinzi in combination with chemotherapy before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy. The Committee for Medicinal Products for Human Use of the European Medicines Agency based its positive opinion on event-free survival and overall survival data from the MATTERHORN Phase III trial, the company announced.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca begins trading on New York Stock Exchange
- AstraZeneca Stock (AZN) Hits NYSE — Should US Investors Pay Attention?
- AstraZeneca Advances AZD5148: Early Safety Data Strengthens Its Infectious Disease Pipeline
- AstraZeneca announces collaboration agreement with CSPC
- AstraZeneca (AZN) Moves Deeper into Weight Loss Market with New $18.5B CSPC Agreement